LSU Health Shreveport
LSU Health Shreveport
Shreveport, Louisiana, United States5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | CNS demyelinating autoimmune disease, Nutritional and Metabolic Diseases, TDP-43 proteinopathy, acute stress disorder, adjustment disorder, amyotrophic lateral sclerosis, anxiety disorder, autoimmune disease, autoimmune disorder of the nervous system, central nervous system disorder, demyelinating disease, depressive disorder, idiopathic pulmonary fibrosis, immune system disorder, interstitial lung disease, lung disorder, metabolic disease, motor neuron disorder, multiple sclerosis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, psychiatric disorder, pulmonary fibrosis, respiratory system disorder, spinal cord disorder | Recruiting | Phase 2 | 2026-09-15 | NCT07002034 | |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-13 | NCT06309966 | |
| Long-term Safety and Tolerability of BHV-7000 | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Enrolling by invitation | Phase 2 | 2026-05-01 | NCT06443463 | |
| RESPONDER-HF Trial | cardiovascular disorder, diastolic heart failure, heart disorder, heart failure | Active, not recruiting | Not applicable | 2026-03-18 | NCT05425459 | |
| Psilocybin for Methamphetamine Addiction | Chemically-Induced Disorders, psychiatric disorder, substance-related disorder | Recruiting | Early phase 1 | 2025-10-07 | NCT06899594 |